would like to highlight Immune Therapeutics, Inc.
), a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body’s natural immune system, the company’s pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.
In the company’s news,
Immune Therapeutics, Inc. (OTCQB: IMUN) centers its works on applying its patented immunotherapy to fight chronic diseases, such as cancer, which affect people of all ages and races all over the world. Leveraging the body’s natural immune system, the company’s product line and immunotherapy technologies are engineered to enhance treatment for those suffering with HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.
One of IMUN’s promising treatments is Low Dose Naltrexone (LDN), or Lodonal, as it is known on a global scale. Lodonal has its origins in the FDA-approved 50mg Naltrexone. Initially known to treat opiate dependencies, the Immune Therapeutics patented treatment, which covers a wide range of indications, is currently used as an immune modulator. Lodonal /LDN works by boosting levels of endorphins (peptides produced in the brain and adrenal glands). These natural peptides are very effective modulators of the immune system. When patients take Lodonal, it attaches to opioid receptors in the brain and immune cells and temporarily blocks endorphins signaling the body in order to increase endorphin production. The increased endorphin production facilitates the activity of stem cells, macrophages, natural killer cells, T and B cells and other immune cells. Lodonal is also effective in preventing immune system over activity, the core of autoimmune disorders, and reduces the release of inflammatory and neurotoxic chemicals in the brain.
New York physician Dr. Bernard Bihari, who has studied immune responses primarily in HIV/AIDs patients, has produced a three-point mechanistic approach to the use of LDN showing the following three distinct increases within the immune system. The first increase is within met-enkephalin (an endorphin produced in large amounts in the adrenal medulla) and endorphin in the blood stream. The second increase occurs within the number and density of opiate receptors on the tumor cell membranes, thereby making them more responsive to the growth-inhibiting effects of the already present levels of endorphins, which in turn induces apoptosis in the cancer cells. Third, increases are stimulated within absolute numbers of circulating cytotoxic T cells (CD8+/TH1) and natural killer cells (“NK cells”), as well as NK cell activity.
IMUN focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS, autoimmune diseases, and immune disorders in the United States. Currently, the company is developing IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. The company is headquartered in Orlando, Florida.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.